Verici Dx (LON:VRCI) Trading Down 14.4% – Should You Sell?

Verici Dx plc (LON:VRCIGet Free Report)’s stock price traded down 14.4% during trading on Friday . The stock traded as low as GBX 2.54 ($0.03) and last traded at GBX 2.89 ($0.04). 2,161,686 shares changed hands during trading, an increase of 232% from the average session volume of 651,979 shares. The stock had previously closed at GBX 3.38 ($0.04).

Verici Dx Price Performance

The company has a debt-to-equity ratio of 4.64, a current ratio of 4.54 and a quick ratio of 8.49. The firm’s 50 day moving average is GBX 3.77 and its 200 day moving average is GBX 4.31. The firm has a market cap of £8.62 million, a P/E ratio of -1.65 and a beta of 1.59.

Verici Dx Company Profile

(Get Free Report)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.

Featured Stories

Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.